Zobrazeno 1 - 10
of 286
pro vyhledávání: '"N S Reed"'
Autor:
E. Nichols, J. A. Deal, B. K. Swenor, A. G. Abraham, N. M. Armstrong, K. Bandeen-Roche, M. C. Carlson, M. Griswold, F. R. Lin, T. H. Mosley, P. Y. Ramulu, N. S. Reed, A. R. Sharrett, A. L. Gross
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Item response theory (IRT) methods for addressing differential item functioning (DIF) can detect group differences in responses to individual items (e.g., bias). IRT and DIF-detection methods have been used increasingly often to i
Externí odkaz:
https://doaj.org/article/92a31ccb482e4220bae8dac2d8d928cf
Publikováno v:
Medical Oncology. 28:766-770
Small cell carcinomas of the ovary (SCCO) are rare and aggressive malignant neoplasms carrying a poor prognosis. Although multi-modality treatment including chemotherapy leads to a high initial response rate, the majority of these patients relapse qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4514eda645968438358929fe52f696c9
https://doi.org/10.1007/s12032-010-9509-0
https://doi.org/10.1007/s12032-010-9509-0
Autor:
Soylemez, Emre1 (AUTHOR) emresoylemez@karabuk.edu.tr, Soylemez, Tugce Gurel2 (AUTHOR), Apaydin, Aydin Sinan3 (AUTHOR), Apaydin, Zuhal Koc4 (AUTHOR), Yasar, Murat5 (AUTHOR)
Publikováno v:
Brain & Behavior. Nov2024, Vol. 14 Issue 11, p1-8. 8p.
Publikováno v:
British Journal of Cancer
Oral capecitabine is a highly active, well-tolerated and convenient treatment for breast and colorectal cancer. This trial assessed the efficacy and safety of single-agent capecitabine in patients with previously treated ovarian cancer. A total of 29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2703712f03a2f9c8c4f34d154a82e157
https://doi.org/10.1038/sj.bjc.6601381
https://doi.org/10.1038/sj.bjc.6601381
Publikováno v:
British Journal of Cancer
The docetaxel–carboplatin combination is active and well tolerated in patients with epithelial ovarian cancer. We added epirubicin to this combination to investigate additional benefits of anthracyclines in epithelial ovarian cancer. Twenty-one pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b8eafc2c0752e5568bed33ecdb754e
http://europepmc.org/articles/PMC2375366
http://europepmc.org/articles/PMC2375366
Autor:
J. B. Neilly, Robert J. Mairs, N. S. Reed, J. Prosser, S. H. Cunningham, A. A. Bolster, T. E. Hilditch, J Owens
Publikováno v:
Nuclear Medicine Communications. 21:437-440
Radioiodinated meta-iodobenzylguanidine (MIBG) is used routinely for imaging and targeted radiotherapy of tumours derived from the neural crest. Since active uptake of MIBG by the noradrenaline transporter (NAT) makes a greater contribution to total
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa6f62dced2fa0d3554328b76b5a5714
https://doi.org/10.1097/00006231-200005000-00005
https://doi.org/10.1097/00006231-200005000-00005
Autor:
Andrew G.N. Robertson, Ajaypal S. Sandhu, N. S. Reed, James Paul, Stuart G. McNee, Paul Symonds
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 40:575-581
Purpose: To report our experience in the use of interstitial iridium-192 implantation combined with external radiotherapy in anal cancer. Methods and Matarials: From 1984 to 1994, 79 patients with anal cancer were treated with radical intent using ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4575ec35643682f743cdc07df6aec72
https://doi.org/10.1016/s0360-3016(97)00814-6
https://doi.org/10.1016/s0360-3016(97)00814-6
Autor:
N. S. Reed, D. Dunlop, M. Soukop, W. Steward, M. M. Eatock, Eric J Fitzsimmons, S. Anderson, N. P. Lucie, P. Tansey, James Paul
Publikováno v:
Clinical Oncology. 10:107-114
This study was intended to ascertain whether the adjunctive administration of filgrastim (r metHuG-CSF, Amgen) would influence the dose intensity of chemotherapy or the morbidity of myelosuppression in patients receiving MOPP or MOPP/EVAP hybrid chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aae69e5fa50c4d8d7f9f1141a1968014
https://doi.org/10.1016/s0936-6555(05)80490-x
https://doi.org/10.1016/s0936-6555(05)80490-x
Autor:
Allan B. MacLean, CR Lewis, Stan B. Kaye, Derek Cruickshank, S. M. Crawford, J. Kennedy, David E. Parkin, James Paul, Henry C Kitchener, T. K. Sarkar, N. S. Reed, H.K. Gordon, M. Soukop, R. Atkinson, R P Symonds, Jim Cassidy, I. D. Duncan, E M Rankin, J. Davis
Publikováno v:
Journal of Clinical Oncology. 14:2113-2119
PURPOSE In 1992, we reported the first results of a randomized study in ovarian cancer, comprising two doses of cisplatin and indicated a significant difference (P = .0008) in median survival. Four years later, we now describe the results of this tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1628d763798a1d1ca31a365626ede196
https://doi.org/10.1200/jco.1996.14.7.2113
https://doi.org/10.1200/jco.1996.14.7.2113